transferrin-abrin variant conjugate

Transferrin-abrin variant conjugate is an experimental immunotoxin designed for the targeted treatment of malignancies overexpressing the transferrin receptor (TfR), such as glioblastoma multiforme and melanoma. The conjugate utilizes human diferric transferrin as a targeting ligand to deliver a variant of the potent plant toxin abrin into cancer cells. Upon binding to TfR and subsequent internalization, the abrin moiety inhibits protein synthesis by enzymatically inactivating the 28S ribosomal RNA, leading to cell death. In vitro studies have demonstrated high cytotoxic potency, which can be significantly enhanced by the addition of monensin. Research has primarily focused on its potential application against glioblastoma multiforme and leptomeningeal neoplasia.

Other names

transferrin-abrin variant immunotoxin